Biosimilar Contract Manufacturing Market To Grow More Than 100% In The Next 6 Years, The Market Will Reach USD 5.5 Billion By 2027 - Arizton

Chicago, IL /PRNewswire/ - According to Arizton's latest research report, the biosimilar contract manufacturing market is expected to grow at a CAGR of 16.19% from 2021 to 2027. With its largest share in 2021, Europe will continue dominating the global biosimilar contract manufacturing market. The robust pipeline of biosimilars, combined with favorable regulations, has contributed to an increase in the number of approvals and launches of novel biosimilars. As a result, the scenario for outsourcing biosimilar manufacturing has grown in several countries.

Initially, major pharma companies continued to be significant contributors to the growth of the biopharma contract manufacturing market; contributions from biotechnology and life sciences companies have also increased in recent years, particularly as demand for biologics, including biosimilars, is at an all-time high globally. With the market entry of many biotech companies, there will be greater demand for contract manufacturing services in biologics, including the biosimilars market. Outsourcing the manufacturing function will enable biotech firms to introduce their products in the market without investing in building or upgrading their manufacturing units. As the costs of biosimilars must be kept significantly low, it makes sense for drug developers to outsource manufacturing activities to keep costs low. As a result, CMOs are witnessing healthy growth in their business from the biosimilar contract manufacturing market.

Biosimilar Contract Manufacturing Market Report Scope

Click Here to Download the Free Sample Report

The demand for contract manufacturing services is gaining momentum owing to the increase in investments by big pharma companies for the R&D of various biologics and biosimilars. Moreover, the significant advantage of the reduction in overall investment for developing and manufacturing drugs with contract manufacturing is expected to increase the adoption of contract manufacturing services by pharma/biotech companies in the coming years. Leading CMOs are expanding their existing manufacturing capacities to maintain their strong position in the biosimilar contract manufacturing market. For instance, in April 2018, Catalent Pharma Solutions completed a USD 5.5 million expansion program at its 200,000+ square foot Philadelphia, Pennsylvania manufacturing site to provide additional clinical packaging and storage capacity.

Patent Expirations of Branded Biologic Drugs

Biologics has been a rapidly evolving area within the biotechnology sector. Introducing biosimilars where the patents and exclusivity periods of the original biologicals have expired is one way to combat the restrictions on the use of biologicals and the resulting pressure on healthcare budgets. By 2018, biologicals worth more than $68 billion in annual sales lost patent protection. A 20% discount could save $14 billion, while a 30% or 40% discount could save $20 billion or $27 billion, respectively. By 2025 several biologic patents will expire in many countries, which could translate into an opportunity to develop new biosimilars. Europe will be the region with more opportunities.

Additionally, the production of biosimilars is largely being outsourced; this trend of outsourcing is likely to continue in the upcoming years and is largely encouraged by the patent expiration of biologic medications. As a result, there will be an increase in demand for biosimilars made under contract in the near future.

Key Vendors

• Lonza
• Boehringer Ingelheim International GmbH
• Catalent
• FUJIFILM
• Thermo Fischer Scientific
• AbbVie
• Abzena
• AGC Biologic
• Alcami
• Almac Group
• Avid Bioservices
• Biocon
• Element Materials Technology
• Eurofins Scientific
• Fresenius Kabi
• Goodwin Biotechnology
• Kemwell
• mAbxience
• Merck KGaA
• Midas Pharma
• Novartis AG
• Pfizer
• Rentschler Biopharma
• Samsung Biologics
• WuXi Biologics

Market Segmentation

Source:

• Mammalian
• Non-mammalian

Scale of Operation:

• Commercial
• Research

Product:

• Finished Dosage Form (FDF)
• Active Pharmaceutical Ingredients (APIs)

Indication:

• Oncology
• Blood Disorders
• Inflammatory & Autoimmune Disorders
• Others

Geography

• APAC
  • China
  • India
  • Japan
  • South Korea
  • Australia
• North America
  • The US
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • Italy
  • The UK
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • South Arabia
  • The UAE
  • Turkey

Check Out Some of the Top-Selling Related Reports:

Medical Device Contract Manufacturing Market - The global medical device contract manufacturing market size to cross USD 132 billion by 2026, growing at a CAGR of over 10% during the period 2020-2026. The global market is experiencing impressive growth due to a wide range of services offered by contract manufacturers. The increasing demand for cost reduction and decreased time to market products are the major factors driving OEMs to focus and develop partnerships with trusted CMOs for developing, manufacturing, and marketing medical devices. Moreover, the growing geriatric population, the increasing prevalence of minimally invasive surgeries, increased healthcare expenditures, and innovations in the medical technology industry are fueling the need for medical device contract manufacturing. The increasing pressure on OEMs to develop high-quality healthcare equipment, reduce price points, and faster time to market are likely to propel the contract manufacturing market across the globe.

Vaccine Contract Manufacturing Market - The global vaccine contract manufacturing market will reach USD 4 billion by 2026, growing at a CAGR of 13% from 2020-2026. North America contributed the highest revenue, with a market share of 35.40% in the global vaccine contract manufacturing market share in 2020. North America has the most widespread contract manufacturing organizations (CMOs), with nearly 40 CMOs present at several US locations. The US accounted for over 90% of the North American vaccine contract manufacturing market share. The market observes the highest growth in this region due to the presence of major biopharmaceutical companies for clinical studies, increasing populations, the spread of bacterial and viral infections, growing hospitalization, and the growing demand for vaccinations.

Active Pharmaceutical Ingredients (API) Market - The global active pharmaceutical ingredients (API) market size is expected to reach USD 266.80 billion by 2026, growing at a compound annual growth rate (CAGR) of 6.22%. Digitalization, big data, and artificial intelligence are accelerating the transformation of the pharmaceutical industry. The growing trend toward new high-tech therapeutics, with the emergence of novel and innovative delivery systems and the evolution of personalized medicines, will further emphasize the growing demand for advanced Aher. Innovative and Biotech APIs are fueling the demand for APIs across the globe.

Biopharmaceutical Contract Manufacturing Market – The global biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 14.37% from 2022 to 2027. Samsung Biologics is one of the active biopharmaceutical contract manufacturing companies that invested a considerable amount in enhancing their manufacturing capacity by volume. The company is investing around USD 2 billion in its super plant in Incheon, South Korea, with a 256,000 liters capacity. Vendors in the biopharmaceutical contract manufacturing market are actively involved in strategic acquisitions and agreements to develop their proprietary technologies and increase their brand image. Catalent made one such acquisition and expanded its early development capabilities by acquiring Pharmatek Laboratories.

Table of Content

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET SEGMENTATION BY SOURCE

4.3.2 MARKET SEGMENTATION BY SCALE OF OPERATION

4.3.3 MARKET SEGMENTATION BY PRODUCT

4.3.4 MARKET SEGMENTATION BY INDICATION

4.3.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 OVERVIEW

8 PREMIUM INSIGHTS

8.1 MARKET SYNOPSIS

8.1.1 MARKET SEGMENTATION

9 MARKET OPPORTUNITIES & TRENDS

9.1 RISE IN PRODUCT LAUNCHES & APPROVALS OF BIOSIMILARS

9.2 FAVORABLE POLICIES ENCOURAGING USE OF BIOSIMILARS

9.3 PATENT EXPIRATIONS OF BLOCKBUSTER BRANDED BIOLOGIC DRUGS

9.4 RISING POTENTIAL OF BIOSIMILARS IN EMERGING MARKETS

10 MARKET GROWTH ENABLERS

10.1 FAVORABLE PATIENT DEMOGRAPHICS WITH RISE IN DISEASE BURDEN

10.2 ROBUST PIPELINE OF BIOSIMILARS BOOSTING CONTRACT MANUFACTURING

10.3 RISING INVESTMENTS FOR DEVELOPING BIOSIMILARS

10.4 HIGH COST OF BIOLOGICS & SURGE IN DEMAND FOR BIOSIMILARS

11 MARKET RESTRAINTS

11.1 QUALITY CONTROL AND SUPPLY CHAIN ISSUES WITH CONTRACT MANUFACTURING

11.2 COMPLEXITIES & LIMITATIONS INVOLVED IN MANUFACTURING BIOSIMILARS

11.3 HIGH COST OF ESTABLISHING BIOMANUFACTURING FACILITIES

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW

12.2 MARKET SIZE & FORECAST

12.2.1 INSIGHTS BY SOURCE

12.2.2 INSIGHTS BY SCALE OF OPERATION

12.2.3 INSIGHTS BY PRODUCT

12.2.4 INSIGHTS BY INDICATION

12.2.5 INSIGHTS BY GEOGRAPHY

12.3 FIVE FORCES ANALYSIS

12.3.1 THREAT OF NEW ENTRANTS

12.3.2 BARGAINING POWER OF SUPPLIERS

12.3.3 BARGAINING POWER OF BUYERS

12.3.4 THREAT OF SUBSTITUTES

12.3.5 COMPETITIVE RIVALRY

13 SOURCE

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 MAMMALIAN

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.3.3 MAMMALIAN: MARKET BY GEOGRAPHY

13.4 NON-MAMMALIAN

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.4.3 NON-MAMMALIAN: MARKET BY GEOGRAPHY

14 SCALE OF OPERATION

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 COMMERCIAL

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.3.3 COMMERCIAL: MARKET BY GEOGRAPHY

14.4 RESEARCH

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.4.3 RESEARCH: MARKET BY GEOGRAPHY

15 PRODUCT

15.1 MARKET SNAPSHOT & GROWTH ENGINE

15.2 MARKET OVERVIEW

15.3 FINISHED DOSAGE FORM

15.3.1 MARKET OVERVIEW

15.3.2 MARKET SIZE & FORECAST

15.3.3 FINISHED DOSAGE FORM: MARKET BY GEOGRAPHY

15.4 ACTIVE PHARMACEUTICAL INGREDIENT

15.4.1 MARKET OVERVIEW

15.4.2 MARKET SIZE & FORECAST

15.4.3 ACTIVE PHARMACEUTICAL INGREDIENT: MARKET BY GEOGRAPHY

16 INDICATION

16.1 MARKET SNAPSHOT & GROWTH ENGINE

16.2 MARKET OVERVIEW

16.3 ONCOLOGY

16.3.1 MARKET OVERVIEW

16.3.2 MARKET SIZE & FORECAST

16.3.3 ONCOLOGY: MARKET BY GEOGRAPHY

16.4 BLOOD DISORDERS

16.4.1 MARKET OVERVIEW

16.4.2 MARKET SIZE & FORECAST

16.4.3 BLOOD DISORDERS: MARKET BY GEOGRAPHY

16.5 INFLAMMATORY & AUTOIMMUNE DISORDERS

16.5.1 MARKET OVERVIEW

16.5.2 MARKET SIZE & FORECAST

16.5.3 INFLAMMATORY & AUTOIMMUNE DISORDERS: MARKET BY GEOGRAPHY

16.6 OTHERS

16.6.1 MARKET OVERVIEW

16.6.2 MARKET SIZE & FORECAST

16.6.3 OTHERS: MARKET BY GEOGRAPHY

17 GEOGRAPHY

17.1 MARKET SNAPSHOT & GROWTH ENGINE

17.2 GEOGRAPHIC OVERVIEW

18 EUROPE

18.1 MARKET OVERVIEW

18.2 MARKET SIZE & FORECAST

18.2.1 EUROPE: SOURCE

18.2.2 EUROPE: SCALE OF OPERATION

18.2.3 EUROPE: PRODUCT

18.2.4 EUROPE: INDICATION

18.3 KEY COUNTRIES

18.3.1 GERMANY: MARKET SIZE & FORECAST

18.3.2 FRANCE: MARKET SIZE & FORECAST

18.3.3 UK: MARKET SIZE & FORECAST

18.3.4 ITALY: MARKET SIZE & FORECAST

18.3.5 SPAIN: MARKET SIZE & FORECAST

19 NORTH AMERICA

19.1 MARKET OVERVIEW

19.2 MARKET SIZE & FORECAST

19.2.1 NORTH AMERICA: SOURCE

19.2.2 NORTH AMERICA: SCALE OF OPERATION

19.2.3 NORTH AMERICA: PRODUCT

19.2.4 NORTH AMERICA: INDICATION

19.3 KEY COUNTRIES

19.3.1 US: MARKET SIZE & FORECAST

19.3.2 CANADA: MARKET SIZE & FORECAST

20 APAC

20.1 MARKET OVERVIEW

20.2 MARKET SIZE & FORECAST

20.2.1 APAC: SOURCE

20.2.2 APAC: SCALE OF OPERATION

20.2.3 APAC: PRODUCT

20.2.4 APAC: INDICATION

20.3 KEY COUNTRIES

20.3.1 CHINA: MARKET SIZE & FORECAST

20.3.2 SOUTH KOREA: MARKET SIZE & FORECAST

20.3.3 INDIA: MARKET SIZE & FORECAST

20.3.4 JAPAN: MARKET SIZE & FORECAST

20.3.5 AUSTRALIA: MARKET SIZE & FORECAST

21 LATIN AMERICA

21.1 MARKET OVERVIEW

21.2 MARKET SIZE & FORECAST

21.2.1 LATIN AMERICA: SOURCE

21.2.2 LATIN AMERICA: SCALE OF OPERATION

21.2.3 LATIN AMERICA: PRODUCT

21.2.4 LATIN AMERICA: INDICATION

21.3 KEY COUNTRIES

21.3.1 BRAZIL: MARKET SIZE & FORECAST

21.3.2 MEXICO: MARKET SIZE & FORECAST

21.3.3 ARGENTINA: MARKET SIZE & FORECAST

22 MIDDLE EAST & AFRICA

22.1 MARKET OVERVIEW

22.2 MARKET SIZE & FORECAST

22.2.1 MIDDLE EAST & AFRICA: SOURCE

22.2.2 MIDDLE EAST & AFRICA: SCALE OF OPERATION

22.2.3 MIDDLE EAST & AFRICA: PRODUCT

22.2.4 MIDDLE EAST & AFRICA: INDICATION

22.3 KEY COUNTRIES

22.3.1 TURKEY: MARKET SIZE & FORECAST

22.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST

22.3.3 UAE: MARKET SIZE & FORECAST

22.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST

23 COMPETITIVE LANDSCAPE

23.1 COMPETITION OVERVIEW

23.2 MARKET SHARE ANALYSIS

23.2.1 LONZA IN BIOSIMILAR CONTRACT MANUFACTURING MARKET

23.2.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH IN BIOSIMILAR CONTRACT MANUFACTURING MARKET

23.2.3 CATALENT IN BIOSIMILAR CONTRACT MANUFACTURING MARKET

23.2.4 FUJIFILM DIOSYNTH BIOTECHNOLOGIES IN BIOSIMILAR CONTRACT MANUFACTURING MARKET

23.2.5 THERMO FISHER SCIENTIFIC IN BIOSIMILAR CONTRACT MANUFACTURING MARKET

24 KEY COMPANY PROFILES

24.1 LONZA

24.1.1 BUSINESS OVERVIEW

24.1.2 LONZA IN BIOSIMILAR CONTRACT MANUFACTURING MARKET

24.1.3 PRODUCT OFFERINGS

24.1.4 KEY STRATEGIES

24.1.5 KEY STRENGTHS

24.1.6 KEY OPPORTUNITIES

24.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

24.3 CATALENT

24.4 FUJIFILM

24.5 THERMO FISHER SCIENTIFIC

25 OTHER PROMINENT VENDORS

25.1 ABBVIE

25.1.1 BUSINESS OVERVIEW

25.1.2 SERVICE OFFERINGS

25.2 ABZENA

25.3 AGC BIOLOGICS

25.4 ALCAMI

25.5 ALMAC GROUP

25.6 AVID BIOSERVICES

25.7 BIOCON

25.8 ELEMENT MATERIALS TECHNOLOGY

25.9 EUROFINS SCIENTIFIC

25.10 FRESENIUS KABI

25.11 GOODWIN BIOTECHNOLOGY

25.12 KEMWELL

25.13 MABXIENCE

25.14 MERCK KGAA

25.15 MIDAS PHARMA

25.16 NOVARTIS AG

25.17 PFIZER

25.18 RENTSCHLER BIOPHARMA

25.19 SAMSUNG BIOLOGICS

25.20 WUXI BIOLOGICS

26 REPORT SUMMARY

26.1 KEY TAKEAWAYS

26.2 STRATEGIC RECOMMENDATIONS

27 QUANTITATIVE SUMMARY

27.1 MARKET BY SOURCE

27.1.1 EUROPE BY SOURCE SEGMENTATION

27.1.2 NORTH AMERICA BY SOURCE SEGMENTATION

27.1.3 APAC BY SOURCE SEGMENTATION

27.1.4 LATIN AMERICA BY SOURCE SEGMENTATION

27.1.5 MIDDLE EAST & AFRICA BY SOURCE SEGMENTATION

27.2 MARKET BY SCALE OF OPERATION

27.2.1 EUROPE BY SCALE OF OPERATION SEGMENTATION

27.2.2 NORTH AMERICA BY SCALE OF OPERATION

27.2.3 APAC BY SCALE OF OPERATION SEGMENTATION

27.2.4 LATIN AMERICA BY SCALE OF OPERATION

27.2.5 MIDDLE EAST AFRICA BY SCALE OF OPERATION SEGMENTATION

27.3 MARKET BY PRODUCT

27.3.1 EUROPE BY PRODUCT SEGMENTATION

27.3.2 NORTH AMERICA BY PRODUCT SEGMENTATION

27.3.3 APAC BY PRODUCT SEGMENTATION

27.3.4 LATIN AMERICA BY PRODUCT SEGMENTATION

27.3.5 MIDDLE EAST & AFRICA BY PRODUCT SEGMENTATION

27.4 MARKET BY INDICATION

27.4.1 EUROPE BY INDICATION SEGMENTATION

27.4.2 NORTH AMERICA BY INDICATION SEGMENTATION

27.4.3 APAC BY INDICATION SEGMENTATION

27.4.4 LATIN AMERICA BY INDICATION SEGMENTATION

27.4.5 MIDDLE EAST & AFRICA BY INDICATION SEGMENTATION

27.5 MARKET BY GEOGRAPHY

27.5.1 MAMMALIAN SEGMENT BY GEOGRAPHY

27.5.2 NON-MAMMALIAN SEGMENT BY GEOGRAPHY

27.5.3 COMMERCIAL SEGMENT BY GEOGRAPHY

27.5.4 RESEARCH SEGMENT BY GEOGRAPHY

27.5.5 FINISHED DOSAGE FORM SEGMENT BY GEOGRAPHY

27.5.6 ACTIVE PHARMACEUTICAL INGREDIENTS BY GEOGRAPHY

27.5.7 ONCOLOGY SEGMENT BY GEOGRAPHY

27.5.8 BLOOD DISORDERS SEGMENT BY GEOGRAPHY

27.5.9 INFLAMMATION & AUTOIMMUNE DISORDERS SEGMENT BY GEOGRAPHY

27.5.10 OTHERS BY GEOGRAPHY

28 APPENDIX

28.1 ABBREVIATIONS

About Us: 

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.